Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.67 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.64 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | CDC42 | P60953 | 1/20 | 0.64 |
| ▸ | RAC1 | P63000 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13579048 | 1.00 | TDP1 (0.68) | TDP1L3MBTL1PTGS2AKR1C3AKR1C2 | |
| SCHEMBL12742987 | 1.00 | TDP1 (0.68) | TDP1L3MBTL1PTGS2AKR1C3AKR1C2 | |
| SCHEMBL3119083 | 0.95 | PTGS2 (0.62) | TDP1L3MBTL1PTGS2AKR1C3AKR1C2 | |
| SCHEMBL3119087 | 0.95 | PTGS2 (0.62) | TDP1L3MBTL1PTGS2AKR1C3AKR1C2 | |
| SCHEMBL13109330 | 0.95 | PTGS2 (0.62) | TDP1L3MBTL1PTGS2AKR1C3AKR1C2 | |
| SCHEMBL13125440 | 0.91 | PTGS2 (0.58) | TDP1L3MBTL1PTGS2AKR1C3AKR1C2 | |
| SCHEMBL15726409 | 0.91 | PTGS2 (0.58) | TDP1L3MBTL1PTGS2AKR1C3AKR1C2 | |
| SCHEMBL12715087 | 0.91 | PTGS2 (0.58) | TDP1L3MBTL1PTGS2AKR1C3AKR1C2 | |
| SCHEMBL13592731 | 0.90 | TDP1 (0.69) | TDP1L3MBTL1PTGS2AKR1C3AKR1C2 | |
| SCHEMBL18765289 | 0.89 | PTGS2 (0.59) | TDP1L3MBTL1PTGS2AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509469-B2 | Compositions and methods for the treatment of pain and dependence disorders | RIPPLE THERAPEUTICS CORPORATION (CA) | 2025-12-30 | — | — | US | disclosed |
| US-20220274999-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PAIN AND DEPENDANCE DISORDERS | RIPPLE THERAPEUTICS CORPORATION (CA) | 2022-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220274999-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PAIN AND DEPENDANCE DISORDERS | OPRL1, OPRK1, OPRM1 | TDP1 4195/4885L3MBTL1 2449/4885PTGS2 678/4885 |
| US-12509469-B2 | Compositions and methods for the treatment of pain and dependence disorders | OPRD1, OPRL1, OPRM1 | TDP1 4359/4885L3MBTL1 1839/4885PTGS2 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.